Bausch Health Broadens Access To Long-Acting Schizophrenia Treatment In Canada
Bausch Health Canada, a subsidiary of Bausch Health Companies (BHC), announced expanded public reimbursement for PrOKEDI, a long-acting schizophrenia treatment, in seven Canadian provinces and federal drug plans. The Phase 3 PRISMA-3 study showed significant improvements in PANSS and CGI-S scores. BHC stock is up 1.16% at $6.38.
How this was made
The 30-second read
Why it matters
Expanded coverage in seven provinces and federal programs could increase patient access and boost sales, though the overall market size remains modest.
Market read
The news is primarily relevant to BHC shareholders; broader market impact is minimal.
What to watch
Potential pricing negotiations and formulary restrictions could dampen revenue gains.
Background
Bausch Health Canada Inc., a subsidiary of Bausch Health Companies Inc., markets PrOKEDI, a long-acting risperidone injection for schizophrenia.
Ticker impact
Bausch Health announced expanded public reimbursement for its PrOKEDI schizophrenia injection in seven Canadian provinces and federal programs.
likely modest upward pressure as market prices in the expanded Canadian coverage.
New reimbursement in multiple provinces adds revenue potential, but the product is niche and the scale is limited.
Market effects
May signal broader acceptance of long-acting injectables in Canadian mental health market.
Positive for Canadian pharma reimbursement landscape.
Limited to BHC; no broader market impact.
Counterpoint
Reimbursement expansion may be offset by competition from other antipsychotic injectables and limited market size.
Key entities
- CompanyBausch Health Companies Inc.
Parent company of Bausch Health Canada, ticker BHC.
- ProductPrOKEDI
Risperidone extended-release injectable for schizophrenia.
